Company Profile
Suzhou Guochen Biotechnology Co., Ltd.
We are committed to creating a better future for medicine, building a high-end biopharmaceutical service outsourcing brand with excellent service quality, and focusing on providing professional clinical biological sample testing, preclinical pharmacokinetics and toxicology evaluation services to global customers.
Preclinical animal experiments
Relying on the "National Non-human Primate Laboratory Animal Seed Center-Suzhou Center"
Chemical innovative drugs:
Focusing on more than 30 targets such as KRAS, NK-1, GLP-1, NS5A, SARM, EGFR, etc., we have established pharmacokinetic, toxicological, and toxicokinetic evaluation platforms for anti-tumor drugs, neurotransmitter drugs, anesthetic drugs, endocrine drugs, antiviral drugs, anti-resistant bacteria drugs, cardiovascular and cerebrovascular drugs, and immunosuppressive drugs. We have completed 167 in-vivo evaluation projects and 45 in-vitro evaluation projects.
Innovative biological drugs:
Focusing on immune agonists (cytokines, CD3&CD20, CD3&BCMA, TAA&4-1BB, PD-1&IL-2, etc.), immunosuppressants (cytokines, complement-related, etc.), fusion proteins (supalutide, colony stimulating factor, dulaglutide, growth hormone), antibody-drug conjugates (TNF-α, B7-H3 & PD-L1, B7-H3 & EGFR, TROP2, Her2, Her3, Claudin18.2, etc.), peptides (exenatide microspheres, teriparatide, anti-anti-gidide, liraglutide, semaglutide), mRNA vaccines (new coronavirus, HPV), siRNA (high fat), stem cells (AD indications); we have established a pharmacokinetic/toxicological, toxicological, immunotoxicity, and immunogenicity evaluation platform for monoclonal antibody drugs, bispecific drugs, antibody-drug conjugates, fusion proteins, stem cells, mRNA, siRNA, etc. More than 100 in-vivo evaluation projects have been completed.
Clinical biological sample analysis
Innovative drugs and generic drugs biological sample testing
Bioanalysis of innovative clinical drugs (large and small molecules)
Focusing on more than 40 targets such as GLP-1, KRAS, TNF-α, IGF-1R, PD-1, NS5A, SARM, EGFR, etc., we have experience in anti-tumor, anti-viral, anti-resistant bacteria, anti-depression, cardiovascular and cerebrovascular, pulmonary fibrosis, diabetes, Alzheimer's disease, iron overload and other indications. We have completed more than 70 chemical drug bioanalysis projects, more than 30 biological drug bioanalysis projects, and 12 DDI projects . Clinical BE testing
We have experience in complex and difficult-to-test drug projects such as endogenous drugs, unstable drugs, compound drugs, metal element drugs, nano drugs, liposome drugs, inhaled drugs, transdermal drugs, etc. We have completed the analysis and testing of 265 varieties, including more than 50 on-site inspections by the National Bureau, and 127 BE projects have obtained production approvals (21 projects are the first approved ) .
Suzhou Guochen Biotechnology Co., Ltd. is located in Suzhou, China's biomedical innovation center known as "Paradise on Earth". It is committed to creating the future of medicine and building a high-end biomedical service outsourcing brand with excellent service quality. It focuses on providing professional clinical biological sample testing, preclinical pharmacokinetics and toxicology evaluation services to global customers.
Preclinical animal experiments
Relying on the "National Non-human Primate Laboratory Animal Seed Center-Suzhou Center"
Chemical innovative drugs:
Focusing on more than 30 targets such as KRAS, NK-1, GLP-1, NS5A, SARM, EGFR, etc., we have established pharmacokinetic, toxicological, and toxicokinetic evaluation platforms for anti-tumor drugs, neurotransmitter drugs, anesthetic drugs, endocrine drugs, antiviral drugs, anti-resistant bacteria drugs, cardiovascular and cerebrovascular drugs, and immunosuppressive drugs. We have completed 167 in-vivo evaluation projects and 45 in-vitro evaluation projects.
Innovative biological drugs:
Focusing on immune agonists (cytokines, CD3&CD20, CD3&BCMA, TAA&4-1BB, PD-1&IL-2, etc.), immunosuppressants (cytokines, complement-related, etc.), fusion proteins (supalutide, colony stimulating factor, dulaglutide, growth hormone), antibody-drug conjugates (TNF-α, B7-H3 & PD-L1, B7-H3 & EGFR, TROP2, Her2, Her3, Claudin18.2, etc.), peptides (exenatide microspheres, teriparatide, anti-anti-gidide, liraglutide, semaglutide), mRNA vaccines (new coronavirus, HPV), siRNA (high fat), stem cells (AD indications); we have established a pharmacokinetic/toxicological, toxicological, immunotoxicity, and immunogenicity evaluation platform for monoclonal antibody drugs, bispecific drugs, antibody-drug conjugates, fusion proteins, stem cells, mRNA, siRNA, etc. More than 100 in-vivo evaluation projects have been completed.
Clinical biological sample analysis
Innovative drugs and generic drugs biological sample testing
Bioanalysis of innovative clinical drugs (large and small molecules)
Focusing on more than 40 targets such as GLP-1, KRAS, TNF-α, IGF-1R, PD-1, NS5A, SARM, EGFR, etc., we have experience in anti-tumor, anti-viral, anti-resistant bacteria, anti-depression, cardiovascular and cerebrovascular, pulmonary fibrosis, diabetes, Alzheimer's disease, iron overload and other indications. We have completed more than 70 chemical drug bioanalysis projects, more than 30 biological drug bioanalysis projects, and 12 DDI projects . Clinical BE testing
We have experience in complex and difficult-to-test drug projects such as endogenous drugs, unstable drugs, compound drugs, metal element drugs, nano drugs, liposome drugs, inhaled drugs, transdermal drugs, etc. We have completed the analysis and testing of 265 varieties, including more than 50 on-site inspections by the National Bureau, and 127 BE projects have obtained production approvals (21 projects are the first approved ) .